Alpha 2.0
Login Register
» Authors » Subodh Verma

Subodh Verma

Explore the profile of Subodh Verma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 715
Citations 23197
Followers 0
Related Specialties
Cardiology & Vascular Diseases
General Surgery
Endocrinology
Top 10 Co-Authors
Hwee Teoh
Deepak L Bhatt
Bobby Yanagawa
Mohammed Al-Omran
C David Mazer
Adrian Quan
Javed Butler
Mikhail N Kosiborod
Paul W M Fedak
Richard D Weisel
Published In
Circulation
Curr Opin Cardiol
Can J Cardiol
J Am Coll Cardiol
J Thorac Cardiovasc Surg
Affiliations
Soon will be listed here.
Recent Articles
1.
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Bohm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, et al.
Eur Heart J . 2025 Mar; PMID: 40037646
Background And Aims: Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic...
2.
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Aggarwal R, Bhatt D, Szarek M, Cannon C, Leiter L, Inzucchi S, et al.
Lancet Diabetes Endocrinol . 2025 Feb; PMID: 39961315
Background: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual...
3.
Generalizability of SELECT to Cardiac Surgical Patients: Analysis of the TRICS III Randomized Trial
Dhingra N, Verma R, Mazer C, Verma S
JACC Adv . 2025 Feb; 4(3):101597. PMID: 39954345
No abstract available.
4.
Empagliflozin's anti-inflammatory spectrum in type 2 diabetes mellitus: Piecing together the puzzle
Van Linthout S, Spillmann F, Verma S
Eur J Heart Fail . 2025 Feb; PMID: 39939875
No abstract available.
5.
Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery: A Narrative Review
Patel S, Badross M, Dhingra N, Moroney M, Casey J, Ali Hassan S, et al.
Ann Thorac Surg . 2025 Jan; PMID: 39889843
Background: Coronary artery bypass grafting (CABG) remains a cornerstone in the management of coronary artery disease (CAD). In nonurgent surgical revascularization cases, preoperative optimization of modifiable risk factors can improve...
6.
Perioperative and Periprocedural Management of Once-Weekly Insulin Treated Patients
Houlden R, Gilbert J, Khan T, Mazer C, Trinacty J, Verma S, et al.
Endocr Pract . 2025 Jan; PMID: 39884510
No abstract available.
7.
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms
Goldenberg R, Gilbert J, Houlden R, Khan T, Makhija S, Mazer C, et al.
Curr Med Res Opin . 2025 Jan; :1-17. PMID: 39871617
The GLP-1 receptor-based agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2i) are major twenty first century breakthroughs in diabetes and obesity medicine but there are important safety considerations regarding the perioperative and...
8.
SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis
Mazer C, Moody A, Teoh H, Quan A, Elituv R, Vivekanandan T, et al.
Circulation . 2025 Jan; 151(4):351-355. PMID: 39869672
No abstract available.
9.
Association between white blood cell count and coronary artery bypass graft failure: an individual patient data analysis of clinical trials
An K, Sandner S, Peper J, Zhou Y, Ten Berg J, Harik L, et al.
J Cardiothorac Surg . 2025 Jan; 20(1):90. PMID: 39849567
Background: Baseline systemic inflammation is associated with worse long-term outcomes after coronary artery bypass grafting [CABG], but the mechanisms of this association are unclear. This study aims to explore the...
10.
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Davies M, van der Meer P, Verma S, Patel S, Chinnakondepalli K, Borlaug B, et al.
Lancet Diabetes Endocrinol . 2025 Jan; 13(3):196-209. PMID: 39848268
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF...